CORCEPT THERAPEUTICS INC (CORT) – SEC staff letter
2025-12-11 · Re: . Form 10-K for the Fiscal Year Ended December 31, 2024 · Accession 0000000000-25-011477 · Review completed (no further comments)
December 11, 2025 Atabak Mokari Chief Financial Officer Corcept Therapeutics Inc. 101 Redwood Shores Parkway Redwood City, CA 94065 Re: Corcept Therapeutics Inc. Form 10-K for the Fiscal Year Ended December 31, 2024 File No. 000-50679 Dear Atabak Mokari: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Full letter on EDGAR → · Filing index · All CORCEPT THERAPEUTICS INC (CORT) correspondence
Templates & resources
- AICPA & CIMA – SEC reporting resources (AICPA & CIMA · Professional body · Free / member)
- BDO Accounting, Reporting & Compliance Hub (ARCH) (BDO · Firm guide · Free)
- Deloitte DART – Roadmap Series (Deloitte · Firm guide · Free)
- Deloitte Roadmap: SEC Comment Letter Considerations (Deloitte · Firm guide · Free)
- KPMG Financial Reporting View (KPMG · Firm guide · Free)
- PwC Viewpoint (PwC · Firm guide · Free / paid)
- RSM Financial Reporting Resource Center (RSM · Firm guide · Free)
- SEC – EDGAR Full Text Search (SEC · Regulator · Free)